With sweeping executive order, Biden puts drug pricing, anti-competitive strategies in the crosshairsnews2021-07-12T13:51:36+00:00July 12th, 2021|Fierce Pharma|
Pfizer to meet with FDA to discuss COVID-19 boosters, but will the U.S. get on board?news2021-07-12T13:36:42+00:00July 12th, 2021|Fierce Pharma|
Horizon teams up with Olympic champion to raise awareness around Graves’ disease and thyroid eye diseasenews2021-07-12T07:37:02+00:00July 12th, 2021|Fierce Pharma|
Sunovion takes Urovant’s overactive bladder med Gemtesa to primary care docs as promo partnership launchesnews2021-07-12T00:57:40+00:00July 12th, 2021|Fierce Pharma|
Seagen, Astellas’ Padcev snares full approval and expands into second-line treatment on path to blockbuster landnews2021-07-09T20:34:09+00:00July 9th, 2021|Fierce Pharma|
Seagen, Astellas’ Padcev snares full approval and expands into second-line treatment on path to blockbuster landnews2021-07-09T20:34:09+00:00July 9th, 2021|Fierce Pharma|
Seagen, Astellas’ Padcev snares full approval and expands into 2nd-line treatment on path to blockbuster landnews2021-07-09T20:34:09+00:00July 9th, 2021|Fierce Pharma|
Bayer’s Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patientsnews2021-07-09T19:32:54+00:00July 9th, 2021|Fierce Pharma|
Bayer’s Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patientsnews2021-07-09T19:32:54+00:00July 9th, 2021|Fierce Pharma|
FDA chief asks for independent investigation into approval of Biogen’s Alzheimer’s drug Aduhelmnews2021-07-09T17:46:21+00:00July 9th, 2021|Fierce Pharma|
